Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2003 Feb 7;52(3):194–198. doi: 10.1007/s00262-002-0355-6

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties

Jörg Westermann 1, Ida J Körner 1, Joachim Kopp 1, Steffen Kurz 2, Martin Zenke 2, Bernd Dörken 1, Antonio Pezzutto 1
PMCID: PMC11034295  PMID: 12649749

Abstract.

In the past decade there has been increasing evidence that tumor antigen-loaded dendritic cells (DC) are able to elicit anti-tumor T-cell responses. Initial clinical data for different tumor entities are encouraging, with objective tumor regressions being observed in some patients. Since GMP production of DC for clinical vaccination protocols is a time- and cost-intensive procedure, cryopreservation of DC in aliquots ready for clinical use would significantly facilitate DC-based vaccination in the clinic. We asked whether freezing and thawing alters the phenotype or functional properties of DC. DC from healthy volunteers and from patients with chronic myeloid leukemia (CML) were analyzed after freezing and thawing for their viability, morphology, immunophenotype (FACS profile), T-cell stimulatory capacity (mixed lymphocyte reaction) and mobility (time-lapse cinemicroscopy). Our results demonstrate that cryopreservation does not cause significant changes in the phenotype or function of DC, neither in DC from healthy volunteers nor in those from CML patients. Our data indicate that cryopreserved aliquots of DC are suitable for clinical application in DC-based immunotherapy protocols.

Keywords: Dendritic cells Cryopreservation Vaccination

Footnotes

Electronic Publication


Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES